Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
75
ORGO Quote, Financials, Valuation and Earnings
Last price:
$5.61
Seasonality move
:
37.64%
Day range:
$5.49 - $5.77
52-week range:
$2.61 - $7.08
Dividend yield:
0%
P/E ratio:
70.39x
P/S ratio:
1.55x
P/B ratio:
2.79x
Volume:
1.2M
Avg. volume:
2.7M
1-year change:
80.06%
Market cap:
$710.7M
Revenue:
$482M
EPS (TTM):
-$0.10
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ORGO
Organogenesis Holdings, Inc.
|
$99.7M | -$0.09 | 36.31% | 261.45% | $8.50 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.21 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ORGO
Organogenesis Holdings, Inc.
|
$5.60 | $8.50 | $710.7M | 70.39x | $0.00 | 0% | 1.55x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
NNVC
NanoViricides, Inc.
|
$1.24 | $6.50 | $22.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $722.3K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.4M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ORGO
Organogenesis Holdings, Inc.
|
9.56% | -0.228 | 6.12% | 2.73x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ORGO
Organogenesis Holdings, Inc.
|
$107.6M | $22.2M | 0.25% | 0.28% | 14.69% | $844K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Organogenesis Holdings, Inc. vs. Competitors
-
Which has Higher Returns ORGO or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of -255.85%. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital ORGOOrganogenesis Holdings, Inc.71.34% $0.11 $426.8M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About ORGO or NBY?
Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 51.79%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Organogenesis Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Organogenesis Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORGOOrganogenesis Holdings, Inc.2 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is ORGO or NBY More Risky?
Organogenesis Holdings, Inc. has a beta of 1.471, which suggesting that the stock is 47.143% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock ORGO or NBY?
Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORGO or NBY?
Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.55x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORGOOrganogenesis Holdings, Inc.1.55x 70.39x $150.9M $21.6M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns ORGO or NNVC?
NanoViricides, Inc. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of --. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital ORGOOrganogenesis Holdings, Inc.71.34% $0.11 $426.8M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About ORGO or NNVC?
Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 51.79%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that NanoViricides, Inc. has higher upside potential than Organogenesis Holdings, Inc., analysts believe NanoViricides, Inc. is more attractive than Organogenesis Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORGOOrganogenesis Holdings, Inc.2 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is ORGO or NNVC More Risky?
Organogenesis Holdings, Inc. has a beta of 1.471, which suggesting that the stock is 47.143% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock ORGO or NNVC?
Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORGO or NNVC?
Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than NanoViricides, Inc. quarterly revenues of --. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.55x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORGOOrganogenesis Holdings, Inc.1.55x 70.39x $150.9M $21.6M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns ORGO or OGEN?
Oragenics, Inc. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of --. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital ORGOOrganogenesis Holdings, Inc.71.34% $0.11 $426.8M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About ORGO or OGEN?
Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 51.79%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that Oragenics, Inc. has higher upside potential than Organogenesis Holdings, Inc., analysts believe Oragenics, Inc. is more attractive than Organogenesis Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORGOOrganogenesis Holdings, Inc.2 0 0 OGENOragenics, Inc.1 0 0 -
Is ORGO or OGEN More Risky?
Organogenesis Holdings, Inc. has a beta of 1.471, which suggesting that the stock is 47.143% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock ORGO or OGEN?
Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORGO or OGEN?
Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than Oragenics, Inc. quarterly revenues of --. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.55x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORGOOrganogenesis Holdings, Inc.1.55x 70.39x $150.9M $21.6M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns ORGO or PTN?
Palatin Technologies has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of --. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ORGOOrganogenesis Holdings, Inc.71.34% $0.11 $426.8M PTNPalatin Technologies-- -- -- -
What do Analysts Say About ORGO or PTN?
Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 51.79%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Organogenesis Holdings, Inc., analysts believe Palatin Technologies is more attractive than Organogenesis Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORGOOrganogenesis Holdings, Inc.2 0 0 PTNPalatin Technologies0 0 0 -
Is ORGO or PTN More Risky?
Organogenesis Holdings, Inc. has a beta of 1.471, which suggesting that the stock is 47.143% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock ORGO or PTN?
Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORGO or PTN?
Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than Palatin Technologies quarterly revenues of --. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than Palatin Technologies's net income of --. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.55x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORGOOrganogenesis Holdings, Inc.1.55x 70.39x $150.9M $21.6M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns ORGO or TOVX?
Theriva Biologics, Inc. has a net margin of 14.3% compared to Organogenesis Holdings, Inc.'s net margin of --. Organogenesis Holdings, Inc.'s return on equity of 0.28% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital ORGOOrganogenesis Holdings, Inc.71.34% $0.11 $426.8M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About ORGO or TOVX?
Organogenesis Holdings, Inc. has a consensus price target of $8.50, signalling upside risk potential of 51.79%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Theriva Biologics, Inc. has higher upside potential than Organogenesis Holdings, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Organogenesis Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ORGOOrganogenesis Holdings, Inc.2 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is ORGO or TOVX More Risky?
Organogenesis Holdings, Inc. has a beta of 1.471, which suggesting that the stock is 47.143% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock ORGO or TOVX?
Organogenesis Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Organogenesis Holdings, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ORGO or TOVX?
Organogenesis Holdings, Inc. quarterly revenues are $150.9M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Organogenesis Holdings, Inc.'s net income of $21.6M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Organogenesis Holdings, Inc.'s price-to-earnings ratio is 70.39x while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Organogenesis Holdings, Inc. is 1.55x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ORGOOrganogenesis Holdings, Inc.1.55x 70.39x $150.9M $21.6M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
